Search results
Uncover the Hidden Data on This Medical Procedure in Children
Mercola· 4 days ago“They do not publish the results [or] let any independent scientist in to look at that information,” Brian Hooker, chief scientific officer for Children’s Health Defense, said. In 1962, children received just five vaccine doses.
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
WKRN Nashville· 5 days agoCelltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely ...
7 Steps To Accelerate Biopharma Manufacturing Processes
BioresearchOnline· 5 days agoGood manufacturing process capability and control is a critical success factor for emerging...
Human Passage of Schistosoma incognitum, Tamil Nadu, India, and Review of Autochthonous...
Centers for Disease Control and Prevention· 2 days agoIn September 2016, as part of a community-based study on hookworm, stool surveys from ≈8,600 participants were conducted in 45 villages in Thiruvanamalai District, Tamil Nadu, India (3), an ...
Tezepelumab Shows Potential for COPD, Negative Trial Notwithstanding
MedPage Today· 4 days agoAsthma drug may benefit patients with blood eosinophil counts indicative of type 2 inflammation
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with...
Morningstar· 6 days agoPRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...
ALECT2 has a better prognosis than other types of amyloidosis
Arizona Daily Star· 6 days agoROACH: I recently saw a friend who had been diagnosed with ALECT2 amyloidosis, a form of chronic kidney disease that is not well-understood but is considered fatal. ALECT2 is the abnormal deposition of the protein leukocyte chemotactic factor 2.
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 3 days agoSNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better ...
Russell Investments Group Ltd. Lowers Stake in QuidelOrtho Co. (NASDAQ:QDEL)
ETF DAILY NEWS· 6 days agoRussell Investments Group Ltd. decreased its position in QuidelOrtho Co. (NASDAQ:QDEL – Free Report) by 40.8% during the fourth quarter, according to the company in its most recent disclosure ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoAustin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung